Diagnosis and Management of Infantile Hemangioma

esponse. Overall, timolol-treated patients had significantly improved responses compared with
the observation group (p=0.001). One patient in whom timolol was prematurely stopped at 5
months of age had rebound growth, which again regressed with resumption of topical timolol.
In a poor quality prospective cohort study conducted in China, 124 infants < 12 months of
age with superficial IH (≤ 3 mm in height) and without prior treatment or tumor regression were
treated with either topical 0.5% timolol maleate drops three times daily (n=101) or observed (n=
23). 103 Timolol promoted regression in 57 patients (56.4%), controlled growth in 36 patients
(35.6%), and was ineffective in 8 patients (7.9%) compared with the observation group where
regression was seen in one patient (4.3%), controlled growth observed in seven (30.4%), and
continued growth observed in 15 patients (65.2%). Regression and efficacy rates in the timolol
group compared to the observation group were significantly improved (p